期刊
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 96, 期 2, 页码 333-336出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2010.031302
关键词
bone; bortezomib; PTH; myeloma
类别
资金
- Millennium/Takeda Pharmaceuticals, Cambridge, Massachusetts
- General Clinical Research Center [M01RR14288]
- Carl L. Nelson Chair of Orthopaedic Creativity
We prospectively evaluated the bone changes associated with proteasome inhibition using single agent bortezomib in relapsed or refractory myeloma patients. Ten patients received bortezomib 1.3 mg/m(2) per days 1, 4, 8 and 11 for three 21-day cycles, and 6 patients received 1 mg/m(2) per day with the same schedule. Bone architecture and metabolism changes were assessed by bone markers, micro-CT, bone histomorphometry, tetracycline labeling and serum parathormone levels. Bone parameter variations were compared by response to treatment. Microarchitectural changes were observed in all evaluable responsive patients. Bone alkaline phosphatase changes were associated with disease response (aPR vs. others P=0.03 cycle 1, day 11) serum parathormone levels were also significantly increased (P=0.04 on days 11, 21, 33) in responding individuals. This study demonstrates that the myeloma control produced by proteasome inhibition is associated with bone changes and to a discrete pattern of hormonal variation. (Clinicaltrials.gov identifier: NCT00569868)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据